EGFR inhibitor Monoclonal Antibody Cetuximab Cas 205923-56-4
EGFR inhibitor Monoclonal Antibody Cetuximab Cas 205923-56-4
| Product name:Cetuximab | Purity:98% min |
| CAS NO:205923-56-4 | Solubility:Soluble in DMSO |
| Molecular Formula:C6484H10042N1732O2023S36 | Package:Package according to customer requirements |
| Molecular Weight:145781.6 g/mol | Storage:Store at -20℃ |
Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer, metastatic non-small cell lung cancer and head and neck cancer. Cetuximab is a chimeric (mouse/human) monoclonal antibody given by intravenous infusion that is distributed under the trade name Erbitux in the U.S. and Canada by the drug company Bristol-Myers Squibb and outside the U.S. and Canada by the drug company Merck KGaA. In Japan, Merck KGaA, Bristol-Myers Squibb and Eli Lilly have a co-distribution.
Related Products:
Alirocumab; Denosumab; Eculizumab; Evolocumab; Omalizumab; Ustekinumab; Vedolizumab; Trastuzumab; Omalizumab; Nivolumab; Denosumab; Bevacizumab; Aflibercept
[1]. Goldstein NI, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995 Nov;1(11):1311-8.
[2]. Gustafsson H, et al. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model. Cell Biochem Biophys. 2017 Jul 29.
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.